From the Journals
Diabetes targets remain elusive for patients
Cascade of diabetes care in the United States has not improved since 2005.
News
FDA approves Baqsimi nasal powder for emergency hypoglycemia treatment
It is the first glucagon therapy approved for this indication that is administrable without an injection.
From the Journals
Inadequate glycemic control in type 1 diabetes leads to increased fracture risk
Each percentage increase in hemoglobin level was associated with a 7% increase in fracture risk.
Sponsored Supplement
Headline can be up to 255 characters
News
The costs and benefits of SGLT2 inhibitors & GLP-1 RAs
The price tags on these drugs are the biggest barrier to their use.
From the Journals
Metabolic and work productivity gains follow telemonitored exercise
Nearly half of participants in an exercise program achieved at least the scheduled activity target of 150 minutes of physical activity per week....
Conference Coverage
Vitamin D did not reduce progression to type 2 diabetes in D2d trial
SAN FRANCISCO – Vitamin D supplementation failed to significantly reduce the risk of progression from prediabetes to...
Video
AACE 2019: Top takeaways from Yehuda Handelsman and Paul Jellinger
LOS ANGELES – Yehuda Handelsman, MD, and Paul S. Jellinger, MD, summarized some of the key takeaways from this year’...
From the Journals
Fournier gangrene cases surge in patients using SGLT2 inhibitors
Serious complications and death are likely if Fournier gangrene is not recognized.
Conference Coverage
Type 2 diabetes bumps up short-term risk for bone fracture
Evaluation of risk factors for short- and long-term fracture risk may help improve risk stratification in patients with type 2 diabetes.
Conference Coverage
No clear winner for treating neuropathic pain
PHILADELPHIA – More head-to-head trials of treatments for neuropathic pain are needed.
News
New renal, CV disease indication sought for canagliflozin
Canagliflozin is currently indicated for patients with type 2 diabetes but may soon help treat those who also have chronic kidney disease.
From the Journals
Newer antihyperglycemic drugs have distinctive CV, kidney benefits
SGLT2 inhibitors and GLP-1 RAs have different effects on cardiovascular and kidney disease outcomes in patients with type 2 diabetes.
From the Journals
Semaglutide plus SGLT2 inhibitors improves glycemic control in type 2 diabetes
Once-weekly treatment with the GLP-1 RA semaglutide helped most patients with type 2 diabetes on SGLT2 inhibitors meet their glycemic targets and...
From the Journals
Bariatric surgery leads to less improvement in black patients
Black patients who underwent bariatric surgery suffered more overall complications and reported a lower quality of life than white patients.
Conference Coverage
Lessons learned from the PCSK9 inhibitor trials
LOS ANGELES – The higher your risk, the greater your benefit from therapeutic intervention.
News
Tic disorders are associated with obesity and diabetes
Patients with Tourette syndrome or chronic tic disorder have a higher risk for metabolic and cardiovascular health problems, a population-based...
Conference Coverage
SGLT-2 inhibitors promising for heart failure prevention, not treatment
LOS ANGELES – The combination of heart failure and diabetes is particularly lethal.
Conference Coverage
Does reduced degradation of insulin by the liver cause type 2 diabetes?
LOS ANGELES – Hepatic insulin clearance is significantly lower in African Americans, compared with European Americans, a difference that may...
Conference Coverage
‘Payoff will be great’ if we can conquer childhood obesity, expert says
LOS ANGELES – Direct evidence of a link between obesity in youth and adult cardiovascular disease is beginning to emerge.
Conference Coverage
Real-world weight loss with meds approximates RCT results
NASHVILLE, TENN. – The real-world study saw more adverse events – but no attrition from side effects.
